Athira Pharma To Present Results From Phase 2/3 LIFT-AD Clinical Trial Of Fosgonimeton To Treat Alzheimer's Disease
Express News | Athira Pharma Inc - Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Express News | Athira Pharma: Co Has Until April 14, 2025, to Regain Compliance
Express News | Athira Pharma: Receives Nasdaq Non-Compliance Notice
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday